EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN OR

252 
2
NUO "Kazakh-Russian Medical University", Almaty, Republic of Kazakhstan 
3
"Osh State University", Osh, Republic of Kyrgyzstan 
4
"Salymbekov University", Bishkek, Republic of Kyrgyzstan 
5
"Sani Konukoglu Medical University", Gaziantep, Turkey 
6
"Southern Regional Scientific Center of Cardiovascular Surgery", Jalal-Abad, Republic of 
Kyrgyzstan 
Background:
The relationship between systolic blood pressure (SBP) change 
during hospitalization of patients with Arterial Hypertension (AH) and HF with 
mildly reduced ejection fraction (HFmrEF), treated by Sacubitril/Valsartan (S/V) or 
Olmesartan (O), and clinical outcomes has never been thoroughly investigated.
Methods:
A total of 270 patients (S/V, n=136 and O, n=134), hospitalized 
with AH and HFmrEF, from 6 hospitals in Azerbaijan, Kazakhstan, Kyrgyzstan and 
Turkey, were enrolled. The SBP change was calculated by subtracting the discharge 
SBP values from the admission values and then divided into quartiles of SBP change 
for each drug. We compared the group with upper quartile SBP change separately 
under Sacubitril/Valsartan or Olmesartan to the lower 3 quartiles of change. Both 
groups had largely similar demographics and clinical characteristics.
Results:
All-cause mortality rate at 1-year was 24% in S/V group and 22% in 
O group. Whereas patients in the upper SBP change group had significantly higher 
cumulative mortality probability at 1-year (28% vs 20% in S/V group; and 27% vs 
18% in O group; log-rank P <0.001). NT-proBNP decreases during initial 
hospitalization were correlated with SBP changes in both (S/V and O) groups and 
were -456±292 ng/mL for S/V group and -491±313 ng/mL for O group before 
discharge. Subgroup analysis demonstrated that mortality risk was more pronounced 
in patients with admission SBP ≥140 mm Hg for both S/V and O groups.
Conclusion:
SBP change is significantly associated with 1-year all-cause 
mortality, as an increased SBP change is associated with worse prognosis for 
patients with HF with mildly reduced ejection fraction. We believe that this readily 
available marker might facilitate risk stratification of patients and possibly improve 
care.

жүктеу/скачать 4,77 Mb.

Достарыңызбен бөлісу: